Allarity Therapeutics Company Insiders
| ALLR Stock | USD 0.99 0.03 3.13% |
Allarity Therapeutics employs about 5 people. The company is managed by 12 executives with a total tenure of roughly 12 years, averaging almost 1.0 years of service per executive, having 0.42 employees per reported executive. Discussion of Allarity Therapeutics' management performance can provide insight into the enterprise performance.
Allarity |
Allarity Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4772) % which means that it has lost $0.4772 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2182) %, meaning that it created substantial loss on money invested by shareholders. Allarity Therapeutics' management efficiency ratios could be used to measure how well Allarity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Allarity Therapeutics Workforce Comparison
Allarity Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 176. Allarity Therapeutics holds roughly 5.0 in number of employees claiming about 2.84% of equities under Health Care industry.
Allarity Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allarity Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allarity Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Allarity Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alexander Epshinsky over a month ago Acquisition by Alexander Epshinsky of 29496 shares of Allarity Therapeutics subject to Rule 16b-3 | ||
Benjamin Laura over a month ago Acquisition by Benjamin Laura of 25000 shares of Allarity Therapeutics at 1.01 subject to Rule 16b-3 | ||
Alexander Epshinsky over six months ago Disposition of tradable shares by Alexander Epshinsky of Allarity Therapeutics subject to Rule 16b-3 |
Allarity Therapeutics Notable Stakeholders
An Allarity Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Allarity Therapeutics often face trade-offs trying to please all of them. Allarity Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Allarity Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Thomas Jensen | CEO, Founder | Profile | |
| Jeremy Graff | President Officer | Profile | |
| Professor MD | CoFounder | Profile | |
| Joan Brown | Interim Reporting | Profile | |
| Alexander Epshinsky | Chief Officer | Profile | |
| James JD | Chief CEO | Profile | |
| Alexander CPA | Chief Officer | Profile | |
| Steen Knudsen | Founder Officer | Profile | |
| Annie Rasmussen | Chief Operations | Profile | |
| Claus Pedersen | Chief Officer | Profile | |
| Jose MD | Consultant Officer | Profile | |
| MD DrSc | Chief Officer | Profile |
About Allarity Therapeutics Management Performance
The success or failure of an entity such as Allarity Therapeutics often depends on how effective the management is. Allarity Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Allarity management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Allarity management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts. Allarity Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Allarity Therapeutics Workforce Analysis
Traditionally, organizations such as Allarity Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Allarity Therapeutics within its industry.Allarity Therapeutics Manpower Efficiency
Return on Allarity Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.4M | |
| Net Loss Per Executive | 991.8K |
Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.